AbbVie, U of C Choose First Batch of Cancer Research Projects

Pharmaceutical giant AbbVie and University of Chicago have picked their initial set of projects to research cancer, a deadly disease given a renewed focus under the Obama administration. They include a new immunotherapy that could essentially weaponize a person’s immune system to fight tumors; the search for a drug to pair with traditional chemotherapy to treat neuroblastoma, an aggressive cancer that most often affects children; a combination of therapies for lung, head, neck and bladder cancers; and therapies that target prostate cancer for patients who are resistant to typical treatments. Read more.

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.